Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Financial Officer | December 17, 2025 | December 19, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date December 17, 2025 · Filed December 19, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 268,700 |
Reported balance
After 2025-12-17 transaction · row 1
1 source rowRow 1 · 2025-12-17 · Grant · Acquired 121,700 · Balance 268,700 F1: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.13 · Expires 2035-12-17 | Direct | 355,050 |
Reported balance
After 2025-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-17 · Grant · Acquired 355,050 · Balance 355,050 F2: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 17, 2025 Filed Dec 19, 2025 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 355,050 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0000882796-25-000038 · form4.xml · derivative · entry 2 Ghias Babar · CIK 0002076862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 355,050 Underlying: Common Stock · 355,050 shares Expires 2035-12-17 F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:11 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 121,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000882796-25-000038 · form4.xml · nonDerivative · entry 1 Ghias Babar · CIK 0002076862 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,700 F1 · shares: Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 305,000 | $0.00 Strike: $8.55 | $0.00 |
DisclosureSEC source: 0001127602-25-019632 · form4.xml · derivative · entry 2 Ghias Babar · CIK 0002076862 · CFO & Head of Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 305,000 Underlying: Common Stock · 305,000 shares Expires 2035-07-24 F2 · shares: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. F2 · derivative.exercise_date: Inducement grant of employee stock options pursuant to the Stock Incentive Plan, which will become exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| July 24, 2025 Filed Jul 28, 2025 20:09 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 147,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-019632 · form4.xml · nonDerivative · entry 1 Ghias Babar · CIK 0002076862 · CFO & Head of Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,000 F1 · shares: Inducement grant of restricted stock units pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated (the "Stock Incentive Plan"), which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.